Click for best price
Postpemic Era Castration Resistant Prostate Cancer Treatment Market Size, Share 2022
Summary
The global and Chinese economies were hit hard in 2020, and the global GDP grew by 5.9% in 2021. Although the global growth prospects improved and there was a V-shaped rebound, this does not mean that the economy has really recovered to the level before the epidemic. The vast majority of countries are still in the stage of recovery after heavy damage and are far from achieving real recovery.
2022 is a year of continuous recovery. Global supply chain disturbance, geopolitical tension, energy price fluctuation, local labor shortage and rising raw material prices will affect the resilience of economic recovery. The International Monetary Fund (IMF) predicts that the world economy will grow by 4.4% in 2022, of which the U.S. economy will grow by about 4%. Driven by China and India, Asia is expected to become the fastest growing region in the world in 2022. However, China's economic growth has slowed down. The 2022 government work report shows that the expected target of economic growth is set at about 5.5%.
According to research, China has set a growth rate of about 5.5%, which not only focuses on the speed of economic growth, but also anchors the quality of economic development. Scientific and technological innovation, economic and social digitization and green development will be the long-term goals of China's economic development. It is expected that in 2022, major economies such as the United States, Europe and China will introduce more favorable policies to drive the development of switching power supply industry.
(Post-pandemic Era)-Global Castration Resistant Prostate Cancer Treatment Market Segment Research Report 2022?, which aims to sort out the development status and trends of the Castration Resistant Prostate Cancer Treatment industry at home and abroad, estimate the overall market scale of the Castration Resistant Prostate Cancer Treatment industry and the market share of major countries, Castration Resistant Prostate Cancer Treatment industry, and study and judge the downstream market demand of Castration Resistant Prostate Cancer Treatment through systematic research, Analyze the competition pattern of Castration Resistant Prostate Cancer Treatment, so as to help solve the pain points of various stakeholders in Castration Resistant Prostate Cancer Treatment industry. This industry research report combines desktop research, qualitative interviews with insiders or experts and other methods to strive for the objectivity and integrity of conclusions and data.
Regional Segmentation (Value; Revenue, USD Million, 2018-2028) of Castration Resistant Prostate Cancer Treatment Market by Research Include
USA
Europe
China
Japan
India
Korea
Southeast Asia
Competitive Analysis; Who are the Major Players in Castration Resistant Prostate Cancer Treatment Market?
Active Biotech
Diagnocure
Glaxosmithkline
Northwest Biotherapeutics
Millennium Pharmaceuticals
Hologic
Spectrum Pharmaceuticals
Abbott Laboratories
Bayer Healthcare Pharmaceuticals
Major Type of Castration Resistant Prostate Cancer Treatment Covered in Research report:
Hormonal Therapy
Adding An Anti-Androgen
Stopping An Anti-Androgen
Estrogens
Chemotherapy
Radiation Therapy
Others
Application Segments Covered in Research Market
Hospital
Ambulatory Surgical Centers
For any other requirements, please feel free to contact us and we will provide you customized report.
| Report Attributes |
Report Details |
| Report Title |
(Post-pandemic Era)-Global Castration Resistant Prostate Cancer Treatment Market Segment Research Report 2022 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
81 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
Table of Contents
Global Castration Resistant Prostate Cancer Treatment Market Segment Research Report 2022
1. Research Scope
2. Market Overview
2.1 Product Introduction, Application, Picture
2.2 Global Castration Resistant Prostate Cancer Treatment Market by Value
2.2.1 Global Castration Resistant Prostate Cancer Treatment Revenue by Type
2.2.2 Global Castration Resistant Prostate Cancer Treatment Market by Value
2.3 Global Castration Resistant Prostate Cancer Treatment Market by Sales
2.3.1 Global Castration Resistant Prostate Cancer Treatment Sales by Type
2.3.2 Global Castration Resistant Prostate Cancer Treatment Market by Sales
3. The Major Driver of Castration Resistant Prostate Cancer Treatment Industry
3.1 Historical & Forecast Global Castration Resistant Prostate Cancer Treatment Sales and Revenue (2018-2028)
3.2 Largest Application for Castration Resistant Prostate Cancer Treatment (2018-2028)
3.3 The Major Downstream Company in China Market 2022
4. Global and Regional Castration Resistant Prostate Cancer Treatment Market
4.1 Regional Market Size in Terms of Sales (2022 & 2028)
4.2 Regional Market Share in Terms of Revenue (2022 & 2028)
4.3 Concentration Ratio (CR5& CR10) of Castration Resistant Prostate Cancer Treatment Market
4.4 Mergers & Acquisitions, Expansion Plans
5. US Castration Resistant Prostate Cancer Treatment Sales (2018-2028)
5.1 Current and Estimated Sales Breakdown by Type (2018-2028)
5.2 Current and Estimated Sales Breakdown by Application (2018-2028)
5.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
5.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
6. Europe Castration Resistant Prostate Cancer Treatment Sales (2018-2028)
6.1 Current and Estimated Sales Breakdown by Type (2018-2028)
6.2 Current and Estimated Sales Breakdown by Application (2018-2028)
6.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
6.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
7. China Castration Resistant Prostate Cancer Treatment Sales (2018-2028)
7.1 Current and Estimated Sales Breakdown by Type (2018-2028)
7.2 Current and Estimated Sales Breakdown by Application (2018-2028)
7.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
7.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
8. Japan Castration Resistant Prostate Cancer Treatment Sales (2018-2028)
8.1 Current and Estimated Sales Breakdown by Type (2018-2028)
8.2 Current and Estimated Sales Breakdown by Application (2018-2028)
8.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
8.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
9. India Castration Resistant Prostate Cancer Treatment Sales (2018-2028)
9.1 Current and Estimated Sales Breakdown by Type (2018-2028)
9.2 Current and Estimated Sales Breakdown by Application (2018-2028)
9.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
9.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
10. Korea Castration Resistant Prostate Cancer Treatment Sales (2018-2028)
10.1 Current and Estimated Sales Breakdown by Type (2018-2028)
10.2 Current and Estimated Sales Breakdown by Application (2018-2028)
10.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
10.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
11. Southeast Asia Castration Resistant Prostate Cancer Treatment Sales (2018-2028)
11.1 Current and Estimated Sales Breakdown by Type (2018-2028)
11.2 Current and Estimated Sales Breakdown by Application (2018-2028)
11.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
11.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
12. South America Castration Resistant Prostate Cancer Treatment Sales (2018-2028)
12.1 Current and Estimated Sales Breakdown by Type (2018-2028)
12.2 Current and Estimated Sales Breakdown by Application (2018-2028)
12.3 Current and Estimated Revenue Breakdown by Type (2018-2028)
12.4 Current and Estimated Revenue Breakdown by Application (2018-2028)
13. Global Castration Resistant Prostate Cancer Treatment Average Price Trend
13.1 Market Price for Each Type of Castration Resistant Prostate Cancer Treatment in US (2018-2022)
13.2 Market Price for Each Type of Castration Resistant Prostate Cancer Treatment in Europe (2018-2022)
13.3 Market Price for Each Type of Castration Resistant Prostate Cancer Treatment in China (2018-2022)
13.4 Market Price for Each Type of Castration Resistant Prostate Cancer Treatment in Japan (2018-2022)
13.5 Market Price for Each Type of Castration Resistant Prostate Cancer Treatment in India (2018-2022)
13.6 Market Price for Each Type of Castration Resistant Prostate Cancer Treatment in Korea (2018-2022)
13.7 Market Price for Each Type of Castration Resistant Prostate Cancer Treatment in Southeast Asia (2018-2022)
13.8 Market Price for Each Type of Castration Resistant Prostate Cancer Treatment in South America (2018-2022)
14. Industrial Chain (Impact of COVID-19)
14.1 Castration Resistant Prostate Cancer Treatment Industrial Chain Analysis
14.2 Downstream
14.3 Impact of COVID-19
14.4 Post-pandemic Era
14.5 Technology Trends of Castration Resistant Prostate Cancer Treatment
15. Castration Resistant Prostate Cancer Treatment Competitive Landscape
15.1 Active Biotech
15.1.1 Active Biotech Company Profiles
15.1.2 Active Biotech Product Introduction
15.1.3 Active Biotech Castration Resistant Prostate Cancer Treatment Sales, Revenue (2018-2022)
15.1.4 Strategic initiatives
15.2 Diagnocure
15.2.1 Diagnocure Company Profiles
15.2.2 Diagnocure Product Introduction
15.2.3 Diagnocure Castration Resistant Prostate Cancer Treatment Sales, Revenue (2018-2022)
15.2.4 Strategic initiatives
15.3 Glaxosmithkline
15.3.1 Glaxosmithkline Company Profiles
15.3.2 Glaxosmithkline Product Introduction
15.3.3 Glaxosmithkline Castration Resistant Prostate Cancer Treatment Sales, Revenue (2018-2022)
15.3.4 Strategic initiatives
15.4 Northwest Biotherapeutics
15.4.1 Northwest Biotherapeutics Company Profiles
15.4.2 Northwest Biotherapeutics Product Introduction
15.4.3 Northwest Biotherapeutics Castration Resistant Prostate Cancer Treatment Sales, Revenue (2018-2022)
15.4.4 Strategic initiatives
15.5 Millennium Pharmaceuticals
15.5.1 Millennium Pharmaceuticals Company Profiles
15.5.2 Millennium Pharmaceuticals Product Introduction
15.5.3 Millennium Pharmaceuticals Castration Resistant Prostate Cancer Treatment Sales, Revenue (2018-2022)
15.5.4 Strategic initiatives
15.6 Hologic
15.6.1 Hologic Company Profiles
15.6.2 Hologic Product Introduction
15.6.3 Hologic Castration Resistant Prostate Cancer Treatment Sales, Revenue (2018-2022)
15.6.4 Strategic initiatives
15.7 Spectrum Pharmaceuticals
15.7.1 Spectrum Pharmaceuticals Company Profiles
15.7.2 Spectrum Pharmaceuticals Product Introduction
15.7.3 Spectrum Pharmaceuticals Castration Resistant Prostate Cancer Treatment Sales, Revenue (2018-2022)
15.7.4 Strategic initiatives
15.8 Abbott Laboratories
15.8.1 Abbott Laboratories Company Profiles
15.8.2 Abbott Laboratories Product Introduction
15.8.3 Abbott Laboratories Castration Resistant Prostate Cancer Treatment Sales, Revenue (2018-2022)
15.8.4 Strategic initiatives
15.9 Bayer Healthcare Pharmaceuticals
15.9.1 Bayer Healthcare Pharmaceuticals Company Profiles
15.9.2 Bayer Healthcare Pharmaceuticals Product Introduction
15.9.3 Bayer Healthcare Pharmaceuticals Castration Resistant Prostate Cancer Treatment Sales, Revenue (2018-2022)
15.9.4 Strategic initiatives
16. Conclusion
17. Methodology and Data Source
LIST OF TABLES & FIGURES
List of Tables and Figures
Figure 1. Total Sales by Application of Castration Resistant Prostate Cancer Treatment Industry (Volume)
Figure 2. Castration Resistant Prostate Cancer Treatment Sales by Regions in 2022
Figure 3. Regional Market Share in Terms of Revenue (2022&2028)
Figure 4. The Top 10 and 5 Players Market Share by Castration Resistant Prostate Cancer Treatment Revenue in 2022
Figure 5. US Castration Resistant Prostate Cancer Treatment Sales (2018-2028)
Figure 6. Sales Breakdown by Type (%)
Figure 7. Sales Breakdown by Type (%)
Figure 8. Sales Breakdown by Application (%)
Figure 9. Revenue Breakdown by Type (%)
Figure 10. Revenue Breakdown by Application (%)
Figure 11. Europe Castration Resistant Prostate Cancer Treatment Sales (2018-2028)
Figure 12. Sales Breakdown by Type (%)
Figure 13. Sales Breakdown by Type (%)
Figure 14. Sales Breakdown by Application (%)
Figure 15. Revenue Breakdown by Type (%)
Figure 16. Revenue Breakdown by Application (%)
Figure 17. China Castration Resistant Prostate Cancer Treatment Sales (2018-2028)
Figure 18. Sales Breakdown by Type (%)
Figure 19. Sales Breakdown by Type (%)
Figure 20. Sales Breakdown by Application (%)
Figure 21. Current and Estimated Revenue Breakdown by Type
Figure 22. Revenue Breakdown by Type (%)
Figure 23. Revenue Breakdown by Application (%)
Figure 24. Japan Castration Resistant Prostate Cancer Treatment Sales (2018-2028)
Figure 25. Sales Breakdown by Type (%)
Figure 26. Sales Breakdown by Type (%)
Figure 27. Sales Breakdown by Application (%)
Figure 28. Revenue Breakdown by Type (%)
Figure 29. Revenue Breakdown by Application (%)
Figure 30. India Castration Resistant Prostate Cancer Treatment Sales (2018-2028)
Figure 31. Sales Breakdown by Type (%)
Figure 32. Sales Breakdown by Type (%)
Figure 33. Sales Breakdown by Application (%)
Figure 34. Revenue Breakdown by Type (%)
Figure 35. Revenue Breakdown by Application (%)
Figure 36. Korea Castration Resistant Prostate Cancer Treatment Sales (2018-2028)
Figure 37. Sales Breakdown by Type (%)
Figure 38. Sales Breakdown by Type (%)
Figure 39. Sales Breakdown by Application (%)
Figure 40. Revenue Breakdown by Type (%)
Figure 41. Revenue Breakdown by Application (%)
Figure 42. Southeast Asia Castration Resistant Prostate Cancer Treatment Sales (2018-2028)
Figure 43. Current and Estimated Sales Breakdown by Type (2018-2028)
Figure 44. Sales Breakdown by Type (%)
Figure 45. Sales Breakdown by Type (%)
Figure 46. Revenue Breakdown by Type (%)
Figure 47. Revenue Breakdown by Application (%)
Figure 48. Industrial Chain
Table 1. Top Manufacturers and Market Segmentation
Table 2. Product Introduction, Application, Picture
Table 3. Castration Resistant Prostate Cancer Treatment Revenue, by Type (Million USD) (2018-2028)
Table 4. Castration Resistant Prostate Cancer Treatment Sales, by Type (K Unit) (2018-2028)
Table 5. Castration Resistant Prostate Cancer Treatment Sales (K Unit) by Application (2018-2028)
Table 6. Castration Resistant Prostate Cancer Treatment Sales (Million USD) by Application (2018-2028)
Table 7. The Major Downstream Company in China
Table 8. Regional Market Share in Terms of Sales (2022)
Table 9. Regional Market Share in Terms of Revenue (2022&2028)
Table 10. Ranking of Global Top Castration Resistant Prostate Cancer Treatment Companies by Revenue, Concentration Ratio in 2022
Table 11. Mergers & Acquisitions, Expansion Plans
Table 12. US Castration Resistant Prostate Cancer Treatment Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 13. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 14. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 15. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 16. Current and Estimated Revenue Breakdown by Type
Table 17. Current and Estimated Revenue Breakdown by Application
Table 18. Europe Castration Resistant Prostate Cancer Treatment Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 19. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 20. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 21. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 22. Current and Estimated Revenue Breakdown by Type
Table 23. Current and Estimated Revenue Breakdown by Application
Table 24. China Castration Resistant Prostate Cancer Treatment Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 25. Table Current and Estimated Sales Breakdown by Type
Table 26. Current and Estimated Sales Breakdown by Type
Table 27. Current and Estimated Sales Breakdown by Application
Table 28. Current and Estimated Revenue Breakdown by Application
Table 29. Japan Castration Resistant Prostate Cancer Treatment Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 30. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 31. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 32. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 33. Current and Estimated Revenue Breakdown by Type
Table 34. Current and Estimated Revenue Breakdown by Application
Table 35. India Castration Resistant Prostate Cancer Treatment Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 36. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 37. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 38. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 39. Current and Estimated Revenue Breakdown by Type
Table 40. Current and Estimated Revenue Breakdown by Application
Table 41. Korea Castration Resistant Prostate Cancer Treatment Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 42. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 43. Current and Estimated Sales Breakdown by Type (2018-2028)
Table 44. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 45. Current and Estimated Revenue Breakdown by Type
Table 46. Current and Estimated Revenue Breakdown by Application
Table 47. Southeast Asia Castration Resistant Prostate Cancer Treatment Sales (K Unit), Market Revenue (Million USD) (2018-2028)
Table 48. Table Current and Estimated Sales Breakdown by Type (2018-2028)
Table 49. Current and Estimated Sales Breakdown by Application (2018-2028)
Table 50. Current and Estimated Revenue Breakdown by Type
Table 51. Current and Estimated Revenue Breakdown by Application
Table 52. Market Price (USD/Unit) for Each Type of Castration Resistant Prostate Cancer Treatment in US (2018-2022)
Table 53. Market Price (USD/Unit) for Each Type of Castration Resistant Prostate Cancer Treatment in Europe (2018-2022)
Table 54. Market Price (USD/Unit) for Each Type of Castration Resistant Prostate Cancer Treatment in China (2018-2022)
Table 55. Market Price (USD/Unit) for Each Type of Castration Resistant Prostate Cancer Treatment in Japan (2018-2022)
Table 56. Market Price (USD/Unit) for Each Type of Castration Resistant Prostate Cancer Treatment in India (2018-2022)
Table 57. Market Price (USD/Unit) for Each Type of Castration Resistant Prostate Cancer Treatment in Korea (2018-2022)
Table 58. Market Price (USD/Unit) for Each Type of Castration Resistant Prostate Cancer Treatment in Southeast Asia (2018-2022)
Table 59. Key Downstream Customer in Each Application Field
Table 60. Active Biotech Profiles
Table 61. Active Biotech Castration Resistant Prostate Cancer Treatment Product Introduction
Table 62. Active Biotech Castration Resistant Prostate Cancer Treatment Sales (Unit), Revenue (Million USD) (2018-2022)
Table 63. Active Biotech Strategic initiatives
Table 64. Diagnocure Profiles
Table 65. Diagnocure Castration Resistant Prostate Cancer Treatment Product Introduction
Table 66. Diagnocure Castration Resistant Prostate Cancer Treatment Sales (Unit), Revenue (Million USD) (2018-2022)
Table 67. Diagnocure Strategic initiatives
Table 68. Glaxosmithkline Profiles
Table 69. Glaxosmithkline Castration Resistant Prostate Cancer Treatment Product Introduction
Table 70. Glaxosmithkline Castration Resistant Prostate Cancer Treatment Sales (Unit), Revenue (Million USD) (2018-2022)
Table 71. Glaxosmithkline Strategic initiatives
Table 72. Northwest Biotherapeutics Profiles
Table 73. Northwest Biotherapeutics Castration Resistant Prostate Cancer Treatment Product Introduction
Table 74. Northwest Biotherapeutics Castration Resistant Prostate Cancer Treatment Sales (Unit), Revenue (Million USD) (2018-2022)
Table 75. Northwest Biotherapeutics Strategic initiatives
Table 76. Millennium Pharmaceuticals Profiles
Table 77. Millennium Pharmaceuticals Castration Resistant Prostate Cancer Treatment Product Introduction
Table 78. Millennium Pharmaceuticals Castration Resistant Prostate Cancer Treatment Sales (Unit), Revenue (Million USD) (2018-2022)
Table 79. Millennium Pharmaceuticals Strategic initiatives
Table 80. Hologic Profiles
Table 81. Hologic Castration Resistant Prostate Cancer Treatment Product Introduction
Table 82. Hologic Castration Resistant Prostate Cancer Treatment Sales (Unit), Revenue (Million USD) (2018-2022)
Table 83. Hologic Strategic initiatives
Table 84. Spectrum Pharmaceuticals Profiles
Table 85. Spectrum Pharmaceuticals Castration Resistant Prostate Cancer Treatment Product Introduction
Table 86. Spectrum Pharmaceuticals Castration Resistant Prostate Cancer Treatment Sales (Unit), Revenue (Million USD) (2018-2022)
Table 87. Spectrum Pharmaceuticals Strategic initiatives
Table 88. Abbott Laboratories Profiles
Table 89. Abbott Laboratories Castration Resistant Prostate Cancer Treatment Product Introduction
Table 90. Abbott Laboratories Castration Resistant Prostate Cancer Treatment Sales (Unit), Revenue (Million USD) (2018-2022)
Table 91. Abbott Laboratories Strategic initiatives
Table 92. Bayer Healthcare Pharmaceuticals Profiles
Table 93. Bayer Healthcare Pharmaceuticals Castration Resistant Prostate Cancer Treatment Product Introduction
Table 94. Bayer Healthcare Pharmaceuticals Castration Resistant Prostate Cancer Treatment Sales (Unit), Revenue (Million USD) (2018-2022)
Table 95. Bayer Healthcare Pharmaceuticals Strategic initiatives
